SCHEMBL991954

SCHEMBL991954

COc1cc(Cl)nc(SC)n1

nearest known ligand 0.44

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.44
KMT2A Q03164 6/20 0.42
MEN1 O00255 4/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
GAA P10253 2/20 0.41
HTT P42858 2/20 0.41
ALDH1A1 P00352 5/20 0.39
LMNA P02545 2/20 0.38
THRB P10828 1/20 0.38
KDM4E B2RXH2 2/20 0.37
TSHR P16473 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8183561 0.86 ALDH1A1 (0.40) POLBSMN1; SMN2ALDH1A1LMNAKDM4E
SCHEMBL5353299 0.85 LMNA (0.45) KMT2AMEN1SMN1; SMN2GAAHTT
SCHEMBL6623489 0.83 KMT2A (0.45) POLBKMT2AMEN1SMN1; SMN2GAA
SCHEMBL62021 0.80 POLB (0.53) POLBKMT2AMEN1SMN1; SMN2GAA
SCHEMBL23908020 0.79 POLB (0.41) POLBKMT2AMEN1SMN1; SMN2GAA
SCHEMBL2387324 0.79 ADORA3 (0.48) POLBKMT2AMEN1SMN1; SMN2GAA
SCHEMBL23884134 0.79 NUDT1 (0.44) POLBKMT2AMEN1SMN1; SMN2GAA
SCHEMBL23884245 0.79 KMT2A (0.49) POLBKMT2AMEN1SMN1; SMN2GAA
SCHEMBL9019845 0.78 POLB (0.40) POLBKMT2AMEN1SMN1; SMN2GAA
SCHEMBL6629111 0.78 RXRA (0.44) KMT2AMEN1SMN1; SMN2GAAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1171116-A4 METHOD FOR THE PREVENTION OR REDUCTION OF CARIOVASCULAR EVENTS ASSOCIATED WITH CORONARY INTERVENTION SMITHKLINE BEECHAM CORP (US) 2004-11-17 EP claimed
EP-1171116-A1 METHOD FOR THE PREVENTION OR REDUCTION OF CARIOVASCULAR EVENTS ASSOCIATED WITH CORONARY INTERVENTION SmithKline Beecham Corporation (US) 2002-01-16 EP claimed
WO-2000045811-A1 METHOD FOR THE PREVENTION OR REDUCTION OF CARIOVASCULAR EVENTS ASSOCIATED WITH CORONARY INTERVENTION SMITHKLINE BEECHAM CORPORATION (US) 2000-08-10 WO claimed
WO-2000046212-A1 METHOD OF PRODUCING SUBSTITUTED PYRIMIDINE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2000-08-10 WO claimed
WO-2025264954-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2025-12-26 WO disclosed
CN-118164965-A Pyrimidine-triazole-fluorine substituted phenyl cyclopropylamine derivative and application thereof 郑州大学 2024-06-11 CN disclosed
US-20240182450-A1 Novel 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses OREGON HEALTH AND SCIENCE UNIVERSITY 2024-06-06 US disclosed
US-11932626-B2 2-pyrimidone analogs as potent antiviral agents against Alphaviruses SOUTHERN RESEARCH INSTITUTE (US) 2024-03-19 US disclosed
CN-117586280-A KRAS G12D inhibitor and application thereof in medicine 贝达药业股份有限公司 2024-02-23 CN disclosed
US-20230120566-A1 Novel 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses OREGON HEALTH AND SCIENCE UNIVERSITY 2023-04-20 US disclosed
US-20230120566-A1 Novel 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses OREGON HEALTH AND SCIENCE UNIVERSITY 2023-04-20 US disclosed
CN-115916175-A Novel 2-pyrimidinone analogs as potent antiviral agents against alphaviruses 南方研究院 2023-04-04 CN disclosed
WO-2004063192-A1 IMIDAZOLYL PYRIMIDINE DERIVATIVES USEFUL AS IL-8 RECEPTOR MODULATORS PHARMACOPEIA DRUG DISCOVERY, INC. (US) 2004-07-29 WO disclosed
US-6537948-B1 Have a wide range of herbicidal spectrum, and causes no phytotoxicity on crops SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2003-03-25 US disclosed
EP-1122244-A1 Uracil compounds and their use SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-08-08 EP disclosed
WO-2000046212-A1 METHOD OF PRODUCING SUBSTITUTED PYRIMIDINE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2000-08-10 WO disclosed
US-5723412-A HERBICIDES KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1998-03-03 US disclosed
US-5599770-A WEED CONTROL; INCLUDING AN ADJUVANT KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1997-02-04 US disclosed
EP-0694538-A2 2-benzyloxy-4-phenoxypyrimidine derivative, processes for producing the derivative and herbicidal composition containing the derivative KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1996-01-31 EP disclosed
EP-0692477-A1 Herbicidal compositions containing 2-benzyloxypyrimidine derivatives KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1996-01-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11932626-B2 2-pyrimidone analogs as potent antiviral agents against Alphaviruses EIF2AK2, ZC3HAV1, MAVS POLB 2683/4885KMT2A 2117/4885MEN1 4254/4885
US-20240182450-A1 Novel 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses EIF2AK2, ZC3HAV1, MAVS POLB 2855/4885KMT2A 2305/4885MEN1 4347/4885
US-20230120566-A1 Novel 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses EIF2AK2, ZC3HAV1, MAVS POLB 2855/4885KMT2A 2305/4885MEN1 4347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.